MedTrace Logo

Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns

NCT01511926 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2015-03-10

No results posted yet for this study

Summary

The most common pain-relievers used by patients with rheumatic disorders are called non-steroidal anti-inflammatory drugs (NSAIDs). These drugs are effective and well documented, but they can cause ulcers and gastrointestinal side effects. Vimovo™ is a tablet containing naproxen (NSAID) and a gastroprotective agent called esomeprazole. Patients with rheumatic disorders, who are at risk for developing gastrointestinal side effects, and where lower doses of naproxen or other NSAID treatment is not considered sufficient, could use this tablet. The regulatory authorities in many European countries have approved the use of Vimovo™, but they would like to understand how various factors influence the doctors' decision to prescribe the tablet and what is characterizing the patients receiving it. The aim of the study is to answer these questions.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Javier Nuevo, MSC · Medical Department, AstraZeneca Spain

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • Belgium
  • Finland
  • Germany
  • Netherlands
  • Norway
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01511926 on ClinicalTrials.gov